For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Histological confirmation of RCC with a clear-cell component, including participants
             who may also have sarcomatoid features

          -  Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC
             Stage IV) RCC

          -  No prior systemic therapy for RCC with the following exception:

             i) One prior adjuvant or neoadjuvant therapy for completely resectable RCC if such
             therapy did not include an agent that targets VEGF or VEGF receptors and if recurrence
             occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy

        Exclusion Criteria:

          -  Any active CNS metastases

          -  Any active, known or suspected autoimmune disease

          -  Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily
             prednisone equivalent) or other immunosuppressive medications within 14 days of
             randomization

          -  Participants who have received a live/attenuated vaccine within 30 days of first
             treatment

        Other protocol defined inclusion/exclusion criteria could apply